Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 18, 2026CureusOpen Access

Time to Relapse Following Rituximab Therapy in Rheumatoid Arthritis and Its Determinants: A Single-Center Observational Study

View Full Paper
Ask AI
Bookmark
Share

Authors

IMIkram El MoubarikIBImane El binouneSRS. Rostom

Discussion

Loading...

Member takes

Overview

Single-center observational study evaluates relapse timing in rheumatoid arthritis patients receiving rituximab, suggesting links to disease activity at treatment start.

Key Points

  • This study aims to evaluate the time to relapse after rituximab therapy in rheumatoid arthritis patients and identify associated factors.
  • Conducted a retro-prospective, single-center observational study from 2021 to 2025
  • Included 97 patients with rheumatoid arthritis treated with rituximab
  • Used Kaplan-Meier analysis for relapse-free survival and regression analyses for factor association
  • Median time to relapse was nine months (IQR 7-11) for both physician-assessed and patient-reported outcomes
  • Lower swollen joint count was significantly associated with longer time to relapse (P = 0.040)
  • Only 37.1% of patients achieved one-year flare-free survival

Cite This Study

Moubarik et al. (2026) studied this question.

synapsesocial.com/papers/6a338cf6630953a74978e1ddhttps://doi.org/10.7759/cureus.110939
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Early predictive factors in routine clinical practice for rituximab therapy response in patients with rheumatoid arthritis2024 · 1 citations
  2. 2Efficacy and retention rate of rituximab in Japanese rheumatoid arthritis patients with a history of other iatrogenic immunodeficiency-associated lymphoproliferative disorders2025
  3. 3Relapses and serious adverse events during rituximab maintenance therapy in ANCA-associated vasculitis: a multicentre retrospective study2024 · 5 citations
  4. 4The Association between the Response to Rituximab with Sociodemographic Data and Disease Characteristics Among a Sample of Iraqi Patients with Rheumatoid Arthritis2024
  5. 5Long-term clinical and radiological effectiveness and safety of ultralow doses of rituximab in rheumatoid arthritis: observational extension of the REDO trial2024 · 4 citations